Teraflex 500 mg + 400 mg 100 capsules

Degenerative-dystrophic diseases of the joints and spine: osteoarthritis stage I - III, osteochondrosis.

Orally. Adults and children over 15 years old are prescribed 1 capsule 3 times a day for the first three weeks; in the following days - 1 capsule 2 times a day, regardless of food intake, with a small amount of water. The recommended duration of treatment is from 3 to 6 months. If necessary, repeated courses of treatment may be conducted, the duration of which is determined individually.

1 capsule contains
Active ingredients:
glucosamine hydrochloride 500 mg, sodium chondroitin sulfate 400 mg.
Excipients: stearic acid 10 mg, magnesium stearate 5 mg, manganese sulfate 1 mg.
Gelatin capsule: gelatin 120 mg.

Transparent hard gelatin capsules No. 00. The contents of the capsules are a powder of white or off-white color with crystalline particles.

Hypersensitivity, severe chronic renal failure, pregnancy, lactation period, age under 15 years.

With caution
Diabetes mellitus (it is recommended to periodically monitor blood glucose levels, especially at the beginning of treatment), bronchial asthma, heart and/or renal failure (isolated cases of edema have been reported with chondroitin use), increased sensitivity to seafood.

Pregnancy and lactation
Clinical data on the efficacy and safety of Teraflex® during pregnancy and lactation (breastfeeding) are lacking.

If undesirable effects from the gastrointestinal tract occur, the dosage of the medication should be reduced by half, and if there is no improvement, the medication should be discontinued.

Teraflex® is well tolerated by patients. Possible side effects include gastrointestinal disturbances (epigastric pain, flatulence, diarrhea, constipation), dizziness, headache, leg pain and peripheral edema, drowsiness, insomnia, tachycardia, allergic reactions.

Symptoms: cases of overdose are unknown. In the event of an overdose of chondroitin sulfate, hemorrhagic rash, nausea, vomiting may occur. Treatment: gastric lavage, symptomatic therapy.

Improves the absorption of tetracyclines, reduces the effect of semi-synthetic penicillins and chloramphenicol. The drug is compatible with NSAIDs and glucocorticosteroids.
There is limited data on the possible interaction between glucosamine and warfarin, which may lead to an increased INR and risk of bleeding. Therefore, when taken simultaneously, coagulation parameters should be monitored.

Stimulates the regeneration of cartilage tissue. Glucosamine and chondroitin sulfate participate in the synthesis of connective tissue, helping to prevent the processes of cartilage destruction and stimulating tissue regeneration. The introduction of exogenous glucosamine enhances the production of cartilage matrix and provides nonspecific protection against chemical damage to cartilage. Another possible action of glucosamine is to protect damaged cartilage from metabolic destruction caused by non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticoids (GCs), as well as its own moderate anti-inflammatory effect.
Chondroitin sulfate serves as an additional substrate for the formation of healthy cartilage matrix. It stimulates the formation of hyaluronan, the synthesis of proteoglycans and type II collagen, and protects hyaluronan from enzymatic degradation (by inhibiting the activity of hyaluronidase); supports the viscosity of synovial fluid, stimulates cartilage repair mechanisms, and suppresses the activity of those enzymes that degrade cartilage (elastase, hyaluronidase). In the treatment of osteoarthritis, it alleviates the symptoms of the disease and reduces the need for NSAIDs.

Glucosamine
Absorption. The bioavailability of glucosamine when taken orally is 25% (first-pass effect through the liver).
Metabolism. After the absorption of an oral dose of radiolabeled glucosamine, it is initially detected in the plasma and later penetrates the tissues. The highest concentrations are found in the liver, kidneys, and joint cartilage. Approximately 30% of the administered dose persists in the tissues of bones and muscles for an extended period.
Elimination. It is primarily excreted by the kidneys in unchanged form; partially through the intestines. The half-life of the drug is 68 hours.

Chondroitin Sulfate
Absorption. When taken orally, a single dose of 0.8 g of chondroitin sulfate (or 0.4 g twice daily) results in plasma concentration increasing over 24 hours. The absolute bioavailability is 12%.
Metabolism. It is metabolized through desulfation.
Elimination. It is excreted by the kidneys. The half-life is 310 minutes.